Quest Diagnostics 3Q 2026: Revenue $3.1B, Net income $312M, EPS $2.78— 10-Q Summary
Quest Diagnostics reported Q3 2026 revenue of $3.1B, net income of $312M, and EPS of $2.78, up 10%, 27.3%, and 28.7% YoY. Requisition volume grew 14.5%, with Corewell Health and Fresenius contributing 9.5 points. Excluding these, volume rose 5% and revenue per requisition increased 1.7%. The company aims for 3% annual cost savings through its Invigorate program.
How this was made
The 30-second read
Why it matters
The earnings beat suggests continued growth in the diagnostic testing market, potentially lifting peer stocks.
Market read
First‑report earnings for a mid‑cap healthcare company with double‑digit growth; likely to move DGX and peers.
What to watch
The partnership with Corewell and Fresenius adds volume but compresses pricing; future guidance remains uncertain.
Background
Quest Diagnostics (DGX) filed its Q3 2026 10‑Q, reporting higher revenue and earnings driven by volume growth and strategic partnerships.
Ticker impact
Quest Diagnostics released its Q3 2026 earnings with revenue of $3.1B, net income $312M and EPS $2.78, all up year‑over‑year.
upward pressure as investors price in better‑than‑expected growth and margin expansion.
Quarterly results show double‑digit revenue and earnings growth, beating prior‑year figures and indicating continued demand for diagnostic services.
Market effects
Boosts outlook for the healthcare diagnostics sector as demand and pricing appear resilient.
Positive for US healthcare stocks, especially other lab and testing companies.
Limited but may influence global diagnostic service providers tracking US earnings trends.
Counterpoint
Margin pressure from lower revenue per requisition could temper upside if cost savings lag.
Key entities
- companyQuest Diagnostics
US‑listed provider of diagnostic testing services.
- partnerCorewell Health
Healthcare partner contributing testing volume.
- partnerFresenius
Healthcare partner contributing testing volume.
